TY  - JOUR
A1  - Schneider, Michael
A1  - Tschöpe, André
A1  - Hanselmann, Doris
A1  - Ballweg, Thomas
A1  - Gellermann, Carsten
A1  - Franzreb, Matthias
A1  - Mandel, Karl
T1  - Adsorber Particles with Magnetically‐Supported Improved Electrochemical Conversion Behavior for Waste Water Treatment Processes
JF  - Particle & Particle Systems Characterization
N2  - Micron‐sized supraparticles, consisting of a plurality of discrete nano‐ and microscale functional units, are assembled and fused by means of a droplet extrusion process. By combining nano magnetite, activated carbon, and conductive carbon with a polymeric binder matrix, particles are obtained which unite good magnetic properties, electrical conductivity, and adsorber activity through the high accessible surface area of the incorporated activated carbon of about 570 m\(^{2}\) g\(^{-1}\), thereby enabling a new approach toward sustainable water treatment processes. Due to the interplay of the components, it is possible to adsorb target substances, dissolved in the water which is demonstrated by the adsorption of the model dye methylene blue. A very fast adsorption kinetic and an adsorption capacity of about 400 mg g\(^{-1}\) is determined. By using the developed composite particles, it is also possible to electrochemically alter substances flowing through a magnetically‐stabilized fluidized‐bed reactor by electrochemically charging/discharging, significantly supported by the magnetic field enabling alternatingly optimum mobility/adsorption phases with contact/charging intervals. The electrochemical conversion can be increased up to 151% depending on the applied flow‐rate and electrical voltage. By applying an external magnetic field, a further increase of electrochemical conversion of up to 70% can be observed.
KW  - composite supraparticles
KW  - dye adsorption
KW  - electrochemical conversion
KW  - magnetic particles
KW  - water purification
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-214738
VL  - 37
IS  - 2
ER  - 
TY  - JOUR
A1  - de Boer, Rudolf A.
A1  - De Keulenaer, Gilles
A1  - Bauersachs, Johann
A1  - Brutsaert, Dirk
A1  - Cleland, John G.
A1  - Diez, Javier
A1  - Du, Xiao-Jun
A1  - Ford, Paul
A1  - Heinzel, Frank R.
A1  - Lipson, Kenneth E.
A1  - McDonagh, Theresa
A1  - Lopez-Andres, Natalia
A1  - Lunde, Ida G.
A1  - Lyon, Alexander R.
A1  - Pollesello, Piero
A1  - Prasad, Sanjay K.
A1  - Tocchetti, Carlo G.
A1  - Mayr, Manuel
A1  - Sluijter, Joost P. G.
A1  - Thum, Thomas
A1  - Tschöpe, Carsten
A1  - Zannad, Faiez
A1  - Zimmermann, Wolfram-Hubertus
A1  - Ruschitzka, Frank
A1  - Filippatos, Gerasimos
A1  - Lindsey, Merry L.
A1  - Maack, Christoph
A1  - Heymans, Stephane
T1  - Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
JF  - European Journal of Heart Failure
N2  - Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction

and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.
KW  - fibrosis
KW  - heart failure
KW  - biomarkers
KW  - fibroblast
KW  - matrix
KW  - prognosis
KW  - imaging
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-223613
VL  - 21
ER  -